Evidence
Life Sci. 2024 Jan 17:122431. doi: 10.1016/j.lfs.2024.122431. Online ahead of print.
ABSTRACT
Liver disease has become one of the main causes of health issue worldwide. Sirtuin (Sirt) 2 is a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, and is expressed in multiple organs including liver, which plays important and complex roles by interacting with various substrates. Physiologically, Sirt2 can improve metabolic homeostasis. Pathologically, Sirt2 can alleviate inflammation, endoplasmic reticulum (ER) stress, promote liver regeneration, maintain iron homeostasis, aggravate fibrogenesis and regulate oxidative stress in liver. In liver diseases, Sirt2 can mitigate fatty liver disease (FLD) including non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD), but aggravate hepatitis B (HBV) and liver ischemia-reperfusion injury (LIRI). The role of Sirt2 in liver cancer and aging-related liver diseases, however, has not been fully elucidated. In this review, these biological processes regulated by Sirt2 in liver are summarized, which aims to update the function of Sirt2 in liver and to explore the potential role of Sirt2 as a therapeutic target for liver diseases.
PMID:38242495 | DOI:10.1016/j.lfs.2024.122431
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
The role of Sirtuin 2 in liver – An extensive and complex biological process
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy
- The role and mechanism of SUMO modification in liver disease
- Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2
- Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Alcohol- and Low-Iron Induced Changes in Antioxidant and Energy Metabolism Associated with Protein Lys Acetylation
- Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
- Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice
- The Beneficial Effect of Brazilian Propolis for Liver Damage through Endoplasmic Reticulum Stress
- Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- From non-alcoholic fatty liver disease to metabolic-associated steatotic liver disease: Rationale and implications for the new terminology
- Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease
- Role of lactate and lactate metabolism in liver diseases (Review)
- Association between nonalcoholic steatohepatitis and high serum ferritin levels in type 2 diabetes mellitus
- Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- Effects of Marine Natural Products on Liver Diseases
- The rs1862513 promoter variant of resistin gene influences susceptibility to nonalcoholic fatty liver disease
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- New nomenclature for fatty liver disease
- Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
- Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
- Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact
- Mitochondrial ACSS1-K635 acetylation knock-in mice exhibit altered metabolism, cell senescence, and nonalcoholic fatty liver disease
- FGL1 and FGL2: emerging regulators of liver health and disease
- Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease
- Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease
- Aging exacerbates oxidative stress and liver fibrosis in an animal model of Down Syndrome
- Hepatic lipopolysaccharide binding protein partially uncouples inflammation from fibrosis in MAFLD
- Discovery of genomic loci for liver health and steatosis reveals overlap with glutathione redox genetics
- Angiocrine signaling in sinusoidal homeostasis and liver diseases
- Hepatic miR-363 promotes non-alcoholic fatty liver disease by suppressing INSIG1
- Paricalcitol attenuates oxidative stress and inflammatory response in the liver of NAFLD rats by regulating FOXO3a and NFκB acetylation
- Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
- Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
- Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
- Haloacetamides disinfection by-products, a potential risk factor for nonalcoholic fatty liver disease
- Sesaminol alters phospholipid metabolism and alleviates obesity-induced NAFLD
- Intricate interplay between cell metabolism and necroptosis regulation in metabolic dysfunction-associated steatotic liver disease: A narrative review
- Metabolic dysfunction-associated fatty liver disease and low muscle strength: A comment
- Near-infrared lipid droplets polarity fluorescent probe for early diagnosis of nonalcoholic fatty liver disease
- The burden of non-alcoholic fatty liver disease in Australia: an analysis of Global Burden of Disease study from 1990 to 2019
- Oleuropein mitigates non-alcoholic fatty liver disease (NAFLD) and modulates liver metabolites in high-fat diet-induced obese mice via activating PPARalpha
- Oleuropein mitigates non-alcoholic fatty liver disease (NAFLD) and modulates liver metabolites in high-fat diet-induced obese mice via activating PPARalpha
- Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
- Roles and Mechanisms of Choline Metabolism in Nonalcoholic Fatty Liver Disease and Cancers
- Hericium erinaceus polysaccharides ameliorate nonalcoholic fatty liver disease via gut microbiota and tryptophan metabolism regulation in an aged laying hen model
- Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
- Asprosin aggravates nonalcoholic fatty liver disease via inflammation and lipid metabolic disturbance mediated by reactive oxygen species
- Liver Fatty Acid-binding Protein Is a More Reliable Biomarker for Liver Injury in Nonalcoholic Steatohepatitis than Other Etiologies of Hepatitis
- Key role of interferon regulatory factor 1 (IRF-1) in regulating liver disease: progress and outlook
- A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice
- The potential role of Akkermansia muciniphila in liver health
- Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis
- Hospital admissions for chronic liver diseases: a temporal study in the South Region of Brazil
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD
- Complex dichotomous links of nonalcoholic fatty liver disease and inflammatory bowel disease: exploring risks, mechanisms, and management modalities
- Exploring factors associated with non-alcoholic fatty liver disease using longitudinal MRI
- Exploring factors associated with non-alcoholic fatty liver disease using longitudinal MRI
- Exploring factors associated with non-alcoholic fatty liver disease using longitudinal MRI
- Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting
Evidence Blueprint
The role of Sirtuin 2 in liver – An extensive and complex biological process
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
The role of Sirtuin 2 in liver – An extensive and complex biological process
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy
- Emerging roles of RNA-binding proteins in fatty liver disease
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- The role and mechanism of SUMO modification in liver disease
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2
- Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- Fatty liver disease's renaming impacts on drug clinical trials
- Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction
- Insights into the role of vitamin D in targeting the culprits of non-alcoholic fatty liver disease
- Endoplasmic reticulum stress in the pathogenesis of alcoholic liver disease
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Alcohol- and Low-Iron Induced Changes in Antioxidant and Energy Metabolism Associated with Protein Lys Acetylation
- The gut-liver axis in fatty liver disease: role played by natural products
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
- The role of N6-methyladenosine methyltransferase RBM15 in non-alcoholic fatty liver disease
- Inflammatory liver diseases and susceptibility to sepsis
- Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
- NLRP3 inflammasome in hepatic diseases: A pharmacological target
- Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Various types of fasting diet and possible benefits in nonalcoholic fatty liver: Mechanism of actions and literature update
- The Beneficial Effect of Brazilian Propolis for Liver Damage through Endoplasmic Reticulum Stress
- Highland barley β-glucan supplementation attenuated hepatic lipid accumulation in Western diet-induced non-alcoholic fatty liver disease mice by modulating gut microbiota
- Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Akkermansia muciniphila - a Potential Next-generation Probiotic for Non-alcoholic Fatty Liver Disease
- The role of endoplasmic reticulum stress-related genes in the diagnosis and subtyping of non-alcoholic fatty liver disease
- Metabolic study of iron deposition based on magnetic resonance in patients with nonalcoholic fatty liver disease
- Corrected and republished from: Metabolic associated liver disease
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- From non-alcoholic fatty liver disease to metabolic-associated steatotic liver disease: Rationale and implications for the new terminology
- Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease
- Role of lactate and lactate metabolism in liver diseases (Review)
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- Association between nonalcoholic steatohepatitis and high serum ferritin levels in type 2 diabetes mellitus
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- Extracellular Vesicles and Fatty Liver
- Activating transcription factor (ATF) 6 upregulates cystathionine β synthetase (CBS) expression and hydrogen sulfide (H2S) synthesis to ameliorate liver metabolic damage
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Review and expert opinion on MAFLD, oxidative stress and multifunctional management
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
- Ufmylation on UFBP1 alleviates non-alcoholic fatty liver disease by modulating hepatic endoplasmic reticulum stress
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Carbon Dots as Potential Therapeutic Agents for Treating Non-Alcoholic Fatty Liver Disease and Associated Inflammatory Bone Loss
- Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome
- The double roles of T cell-mediated immune response in the progression of MASLD